用于缓解严重花生过敏反应的DNA疫苗ASP0892获FDA快通道审批资格

发布时间：2018-03-12 21:15

  本文选题：DNA疫苗ASP　切入点：FDA　出处：《国际药学研究杂志》2017年04期 　论文类型：期刊论文

【摘要】：正阿斯特拉药业公司宣布DNA疫苗ASP0892获FDA快通道审批资格,用于缓解严重的花生过敏反应。该药是应用LAMP-Vax平台生成的新DNA疫苗。Ⅰ期临床试验评价其对花生过敏的免疫反应、耐受性和安全性。花生过敏是威胁生命的致命性过敏,微量暴露即可引起过敏反应。目前尚无批准的有效预防药物,只有携带肾上腺素自动注射器应对意外发生的病例。LAMP-Vax平台是突破性技术,用于多种疾病疫苗研发。它包括编码溶酶体有关的膜蛋白的短DNA序列,利用人体的自然生物化学,产生更完全的免疫反应,包
[Abstract]:DNA vaccine ASP0892 has been approved by FDA Fast Channel for severe peanut allergies. The drug is a new DNA vaccine produced by the LAMP-Vax platform. Phase I clinical trials evaluated its immune response to peanut allergies. Tolerance and safety. Peanut allergies are life-threatening fatal allergies, which can be caused by exposure to small amounts. There is no approved effective prophylactic drug. Only automated epinephrine syringes for accidental cases. The LAMP-Vax platform is a breakthrough technology for developing vaccines for multiple diseases. It includes short DNA sequences that encode lysosomal membrane proteins, using the body's natural biochemistry. Produce a more complete immune response, package
【分类号】：R97
，

本文编号：1603317